Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability Study

NCT: NCT06649955 · RECRUITING

NCT IDNCT06649955
StatusRECRUITING
Start Date2025-02-10
Completion2027-02
SponsorPathMaker Neurosystems Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

Following completion of the ALS Early Feasibility Study of the MyoRegulator® device for treatment of ALS (NCT06165172), the CALM study will further assess the feasibility of the MyoRegulator® device to treat ALS in an expanded number of individuals with ALS. CALM will gather additional preliminary evidence of clinical safety and potential effectiveness in this patient population with a longer follow-up period and additional secondary endpoints in a single-arm study prior to commencing a larger sham-controlled pivotal trial.

Frequently Asked Questions

What is Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability Study?

Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability Study is a clinical trial registered under NCT06649955. Current status: RECRUITING.

What is the status of NCT06649955?

The current status of NCT06649955 (Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability Study) is: RECRUITING.

When did Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability Study start?

Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability Study started on 2025-02-10.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.